BeiGene | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies

⟵ Back to Search Results

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Beigene Study ID

BGB-16673-101

ClinicalTrials.gov ID

NCT05006716

EudraCT Number

2022-502157-33-00

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents